e-7107 and Disease-Models--Animal

e-7107 has been researched along with Disease-Models--Animal* in 1 studies

Other Studies

1 other study(ies) available for e-7107 and Disease-Models--Animal

Article	Year
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI insight, 2018, 10-04, Volume: 3, Issue:19 The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an Eμ-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases. Topics: Adult; Aged; Aged, 80 and over; Alternative Splicing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epoxy Compounds; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Mice; Mice, Transgenic; Middle Aged; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoproteins; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA Splicing Factors; Spliceosomes; Sulfonamides; Thiophenes	2018

Article

Year

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

JCI insight, 2018, 10-04, Volume: 3, Issue:19

The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an Eμ-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases.

Topics: Adult; Aged; Aged, 80 and over; Alternative Splicing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epoxy Compounds; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Mice; Mice, Transgenic; Middle Aged; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoproteins; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA Splicing Factors; Spliceosomes; Sulfonamides; Thiophenes

2018